Recently Featured

UK Sets Out World-Leading Pathway for Space-Manufactured Drugs

March 19, 2026
The UK government has unveiled a pioneering framework aimed at facilitating the commercialization of pharmaceuticals manufactured in space. This initiative represents a significant advancement in the integration of space technology into the pharmaceutical sector, potentially leading to the development of more effective and higher-quality medicines. Historically, the unique microgravity environment of space has been shown…

Affinia receives FDA fast track designation for AFTX-201

March 19, 2026
Affinia Therapeutics has secured fast track designation from the US FDA for its investigational genetic medicine, AFTX-201, aimed at treating BAG3-associated dilated cardiomyopathy (DCM). This designation is a significant milestone as it highlights the FDA’s recognition of the urgent medical need for effective therapies in this area. BAG3-associated DCM is a rare and severe form…

New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products Now Available

March 18, 2026
The FDA has recently introduced a new framework for Clinical Investigation Exclusivity, granting a three-year exclusivity period for certain drug products. This regulatory development aims to incentivize innovation by providing additional market protection for products that undergo new clinical investigations, thereby fostering an environment conducive to research and development. This exclusivity is particularly significant for…

Obesity Drugs May Silence the ‘Drug Noise’ Behind All Addiction

March 18, 2026
Recent advancements in obesity medications, particularly GLP-1 receptor agonists, are reshaping the conversation around addiction treatment. These drugs, originally developed for weight management, are demonstrating potential effects on reducing cravings and altering the brain’s reward pathways, which could lead to significant implications for addiction therapies. The context of this development lies in the growing recognition…

Ongoing Cases